Global Depression Therapeutics Market Analysis
Overview
Antidepressants are used to treat anxiety, stress, and depressive disorder, among other mental illnesses. Several neurotransmitters in the brain, such as dopamine and serotonin, remain in chemical form and are important for emotional equilibrium, such as mood and behavior. Once taken, these medicines have distinct pharmacological actions in the brain to restore the chemical equilibrium in the brain, which is linked to behavioral disorders like depression.
Get Your FREE Sample Copy of the Depression Therapeutics Market Report 2021
Drivers
During the forecast period, the increasing incidences of mental illnesses such as depression and anxiety is projected to increase the market for depression therapies.
Mental illnesses including major depressive disorder, anxiety, and its co-morbidities are quite common worldwide. According to the World Health Organization (WHO), over 300 million individuals worldwide were projected to be depressed in 2017. Moreover, the World Health Organization (WHO) enacted a World Health Assembly resolution in 2013 to manage mental illnesses in a comprehensive and coordinated manner, and its Mental Health Gap Action Program includes depression. Panic, anxiety, post-traumatic stress disorder (PTSD), suicidal behavior, and drug addiction disorder were the top five mental disorders in the Asia Pacific area in 2015, according to the World Health Organization (WHO). The use of depression medicines is anticipated to rise throughout the forecast period as the frequency of mental illnesses rises.
In 2017, the global depression therapeutics market was worth US$ 11,130.7 million, and it is anticipated to grow at a CAGR of 3.7 percent from 2018 to 2026.
Ask for PDF sample copy of the Depression Therapeutics market report @ https://www.coherentmarketinsights.com/insight/request-pdf/1307
During the forecast period, the global depression therapeutics market is predicted to increase due to low antidepressant drug costs and the lack of cheap treatment options.
Drugs or psychotherapy, which includes cognitive behavioral therapy, are used to treat mental illnesses such as depression and anxiety (CBT). Although both therapies have similar levels of efficacy, with 30 percent to 40 percent remission rates, the cost-efficiency of both therapies plays an essential role, according to the American Psychiatric Association in 2017. Due to a shortage of finances, societal stigma associated with mental illnesses, and a shortage of trained psychotherapists, patients frequently do not have access to advanced psychotherapy, in which case medication might be helpful. Antidepressants are commonly accessible due to the large number of generic companies that provide cost-effective medications, but psychotherapy is more expensive and inaccessible elsewhere due to a shortage of qualified psychiatrists. Psychotherapy single sessions can cost anywhere from $60 to $150, according to the Psychotherapy and Counselling Federation of Australia (PACFA). Brain imaging techniques such as electroconvulsive therapy and vagus nerve stimulation are newer therapeutic alternatives that are not generally available and costly. Fisher Wallace developed the Fisher Wallace Stimulator, a U.S. FDA-approved stimulator for treating depression, anxiety, and insomnia that costs approximately US$ 700 and is out of reach for the bulk of the population.
The use of depression medications has been limited due to various negative impacts such as increased suicidal inclination, hormonal imbalances, and stress. Furthermore, companies have been sued several times as a result of these adverse effects, which has demotivated them to spend further in this industry. Even though the generic medicine was made by another firm, Mylan N.V., GlaxoSmithKline was ordered to pay US$ 3 million to a lady whose husband committed suicide after taking a generic form of Paxil, an antidepressant drug. GlaxoSmithKline is accountable and will have to pay penalties since it controls the drug’s design and label, which applies to both generic and branded drugs, according to the verdict.
View Press Release For More Information
Competitive Landscape
Key companies contributing in the global depression therapeutics market include Takeda Pharmaceutical Company Limited, Intellipharmaceutics International, Inc., Apotex, Inc., Allergan Plc, Eli, Lilly and Company, Zhejiang Hua Hai Pharmaceutical Co., Ltd., Pfizer, Inc., Chengdu Kanghong Pharmaceutical Group Co.,Ltd., AstraZeneca, Plc, GlaxoSmithKline Plc, Shionogi & Co. Ltd., Otsuka Holdings Co., Ltd., and H.Lundbeck A/S.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- PEST Analysis
- Porter’s Five Forces Analysis
- Pipeline Analysis
- Market Dynamics
- Global Depression Therapeutics Market, By Drug Type, 2018–2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Segment Trends
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Introduction
- Global Depression Therapeutics Market, By Indication, 2018–2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Major Depressive Disorder (MDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Dysthymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Postpartum Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Seasonal Affective Disorder (SAD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Premenstrual Dysphoric Disorder (PMDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Introduction
- Global Depression Therapeutics Market, By Distribution Channel, 2018–2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Introduction
- Global Depression Therapeutics Market, By Regions, 2018–2026, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2026
- North America
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026, (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- South Africa
- North Africa
- Central Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Section
- References
- Research Methodology
- About Us and Sales Contact
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1307
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837